全世界范围内，受特应性皮炎影响的成人高达2-10%1。我国城市1-7岁儿童特应性皮炎患病率也高达12.94%2。特应性皮炎是一种慢性免疫介导的系统性疾病，无法治愈，极大的影响了患者及其家人的生活3,4。
它不仅是一种“皮肤疾病”患有特应性皮炎的人可以看到它对皮肤的影响，如红肿和皮损，也可以感受到它对日常生活的破坏性影响，包括持续瘙痒、龟裂、结痂和渗出，以及焦虑和抑郁症状。3,5中重度特应性皮炎的特征是可见的皮肤病变，可包括6,7,8许多患有特应性皮炎的人会产生一系列负面情绪，包括 5,9,10,11特应性皮炎给医保系统造成了财政负担它给家庭、卫生体系和社会都带来了沉重的负担12在病情加重期间，患者报告他们10%的工作时间受到影响，这导致欧洲每年总共损失23亿欧元的生产力10中重度特应性皮炎患者急诊次数和住院次数均高于轻度特应性皮炎患者13特应性皮炎不仅仅是一种浅表性皮肤病，它是一种使人衰弱的疾病。只有患者才能表达没有特应性皮炎的生活的真正价值，为什么不问问他们呢？中重度特应性皮炎患者报告 4要点高达30%的儿童病例会持续到成年14高达72%的中重度特应性皮炎患者存在特应性共病15由于特应性皮炎不可预测的性质，欧洲患者报告平均缺勤2.7天10对于患有中重度特应性皮炎的成年人来说，尚未得到满足的医疗需求是有效改善皮肤损伤、减少瘙痒和改善整体生活质量的治疗选择。参考文献(1) Bieber, T., 2010. Atopic Dermatitis. Ann Dermatol, 22(2), pp. 125–137. (2) Guo, Y., et al., “Prevalence of Atopic Dermatitis in Chinese Children aged 1-7 ys”. Scientific reports, vol. 6: pp. 29751, 2016; (3) D. Leung, R. Nicklas and J. Li, “Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters,” Ann Allergy Asthma Immunol, pp. 93(3 Suppl 2):S1-21, 2004. (4) C.L.Carroll, et al. “The burden of atopic dermatitis: Impact on the Patient, family, and Society,” Pediatric Dermatology pp. 22(3)192-9, 2005. (5) J. Whiteley, B. Emir, R. Seitzman, G Makinson, “The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey,” Current Medical research and Opinion, pp. 32(10):1645-51, 2016. (3):491-498, 2016. (6) K. Eyerich, S. Eyerich and T. Biedermann, “The Multi-Modal Immune Pathogenesis of Atopic Eczema,”Trends Immunol, pp. 36(12):788-801, 201. (7) S. Weidinger and N. Novak, “Atopic dermatitis,” Lancet, p. 387:1109–1122, 2016. (8) R. Sidbury, W. Tom and J. Bergman, “Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease areas and use of adjunctive therapies and approaches,” J Am Acad Dermatol, pp. 71:1218–1233, 2014. (9) J. Schmitt, F. Csotonyi and A. Bauer, “Determinants of treatment goals and satisfaction of patients with atopic eczema,” J Dtsch Dermatol Ges, pp. 6(6):458-465, 2008. (10) T. Zuberbier, S. Orlow and A. Paller, “Patient perspectives on the management of atopic dermatitis,” J Allergy Clin Immunol, pp. 118(1):226-232, 2006. (11) A. Torrelo, J. Ortiz and A. Alomar, “Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management,” Eur J Dermatol, pp. 22(1):97-105, 2012. (12) D. Fivenson, R. Arnold and D. Kaniecki, “The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization,” J Manag Care Pharm, pp. 8(5):333-342, 2002. (13) S.M. Shrestha, L. Wang and J. Chao, “Burden of atopic dermatitis: comorbidities, healthcare resource utilization, and costs in US commercial and Medicare adult populations,” Academy of Managed Care Pharmacy (AMCP) Nexus, 2016. (14) D. Garmhausen, T. Hagemann and T. Bieber, “Characterization of different courses of atopic dermatitis in adolescent and adult patients,” Allergy, pp. 68(4):498-506, 2013. (15) E. Simpson, E. Guttman-Yassky and D. Margolis, “Chronicity, comorbidity and life course impairment in atopic dermatitis: insights from a cross-sectional study in US adults,” in 25th European Academy of Dermatology and Venereology, Vienna, Austria, 2016.MAT-CN-2109239有效期：2023年6月4日
